Faculty Members

John Mackey

Medical Oncology
Department of Oncology
University of Alberta
Cross Cancer Institute
11560 University Avenue
Edmonton, Alberta T6G 1Z2
Tel: 780.432.8221


I direct the Clinical Trial Unit at the Cross Cancer Institute, a highly motivated team of investigators and experience staff that enters nearly 15% of our patients on cancer therapy trials, and lead the clinical trial program in breast cancer.   I am Executive Director of Translational Research in Oncology, a global network of academic investigators carrying out trials of novel anticancer drug treatments ( I serve on the steering committees of seven international drug trials.
I Chair the Alberta Pre-Phase 1 Cancer Program that brings Alberta-made anticancer compounds to first-in-human testing, and work with academic collaborators to bring their ideas to the clinic. My translational research program focuses on developing tests to predict which patients are most likely to benefit from anticancer therapy, and exploiting novel targets and pathways to improve systemic cancer therapy.
My research program is funded by the Alberta Cancer Foundation, the Canadian Breast Cancer Research Alliance, the Department of Defense, and multiple industry sponsors.
Research Facilities and Affiliations
My primary academic appointment is in the Division of Medical Oncology in the Department of Oncology. I also hold a cross appointment in the Division of Experimental Oncology.
Google Scholar Citations
Please click on this link for citations, h-index and i10-index



Publications (selected from more than 300 peer reviewed journal publications)
Mackey JR, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press MF, Sauter G, Lindsay M, Houe V, Buyse M, Drevot P, Hitier S, Bensfia S, Eiermann W; Translational Research in Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 investigators. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol. 2016 Jun;27(6):1041-7
Mackey JR, McCarthy N, Gelmon KA, Verma S, Fresco R, Thireau F, Fung H, Martín M. Final Survival Analysis of ROSE/TRIO-012. J Clin Oncol. 2016 Aug 1
Sawyer MB, Pituskin E, Damaraju S, Bies RR, Vos LJ, Prado CM, Kuzma M, Scarfe AG, Clemons M, Tonkin K, Au HJ, Koski S, Joy AA, Smylie M, King K, Carandang D, Damaraju VL, Hanson J, Cass CE, Mackey JR. A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.  Clin Breast Cancer. 2016 Apr;16(2):139-44
Fresco R, Spera G, Meyer C, Cabral P, Mackey JR. Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials. Oncologist. 2015 Jul;20(7):702-12.
Mackey JR, Ramos-Vazques M, Lipatov O, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Abi Gerges D, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martin M. Primary Results of ROSE/ TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab of First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer. J Clin Oncol. 2014 Sep 2. Pii: JCO.2014.57.1513.
Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Winholes J, Pinter T, Rodriguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; for the TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72-80.
Courneya KS, Segal RJ, McKenzie DC, Dong H, Gelmon K, Friedenreich CM, Yasui Y, Reid RD, Crawford JJ, Mackey JR. Effects of Exercise during Adjuvant Chemotherapy on Breast Cancer Outcomes. Med Sci Sports Exerc. 2014 Mar 13. 
Cameron D, Brown J, Dent R, Jackisch C, Mackey JR, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Lae R, Im YJ, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Adjuvant Bevacizumab-Containing Therapy in Triple-Negative Breast Cancer (BEATRICE): Primary Results of Randomized, Phase 3 Trial.  Lancet Oncol. 2013 Sep:14(10):933-42.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey JR, Glaspy J, Chan A, Pawlick M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine. 2011 Oct 6;365(14):1273-83.
Martin M, Pienkowski T, Mackey JR, Pawlick M, Guastalla J-P, Weaver C, Tomiak E, Al-Tweigeri T,Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwel B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C.  A randomized trial of docetaxel in combination with doxorubicin and cyclophosphamide (TAC) as adjuvant treatment of operable node-positive breast cancer. New England Journal of Medicine,  352: 2302-13, 2005.
Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, Verma S, Collins LL, Paterson AH, Robidoux A, Pritchard KI. Controlling angiogenesis in breast cancer; A systematic review of anti-angiogenic trials. Cancer Treat Rev. 2012 Oct;38(6):673-88.
Eiermann  W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III Study of Doxorubicin/Cyclophosphamide with Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients with Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial. J Clin Oncol. 2011 Oct 10;29(29)”3877-84.
Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.  Gastroenterology. 2012 Sep; 143(3):664-74.
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK, Griffith M, Moradian A, Cheng SW, Morin GB, Watson P, Gelmon K, Chia S, Chin SF, Curtis C, Rueda OM, Pharoah PD, Damaraju S, Mackey JR, Hoon K, Harkins T, Tadigotla V, Sigaroudinia M, Gascard P, Tlsty T, Costello JF, Meyer IM, Eaves CJ, Wasserman WW, Jones S, Huntsman D, Hirst M, Caldas C, Marra MA, Aparicio S. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012 Apr 4;486(7403):395-9.
Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Dervenis C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthoney A, Halloran CM, Mayerle J, Olah A, Jackson R, Rawcliffe CL, Scarpa A, Bassi C, Buchler MW; for the European Study Group for Pancreatic Cancer. Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. J Natl Cancer Inst. 2014 Jan;106(1).
Jones LW, Douglas PS, Khouri MG, Mackey JR, Wojdyla D, Kraus WE, Whellan DJ, O’Conno CM. Safety and Efficacy of Aerobic Training in Patients With Cancer Who Have Heart Failure: An Analysis of the HF –ACTION Randomized Trial. J Clin Oncol. 2014 Jul 7. JCO.2013.53.5724.
North S, El-Gehani F, Santos C, Ghosh S, Lai R, Cass CE, Mackey JR. Expression of nucleoside transporters (NT) and deoxycytidine kinase (dCK) proteins in muscle invasive urothelial carcinoma of the bladder (UCCB): correlation with pathologic response to neoadjuvant platinum/gemcitabine combination chemotherapy (NAC). J Urol. 2013 Jul 10.
Mason AL, Gilady SY, Mackey JR. Mouse mammary tumor virus in human breast cancer red herring or smoking gun? American Journal of Pathology.  2011 Oct;179(4):1588-90.
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, MigliaccioI, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with Tamoxifen in patients with hormone receptor-positive metastatic breast cancer; a randomized Phase II study. Clin Cancer Res. 2011 Mar 1;17(5):1147-59.
Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiello-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Banos A, Adewoye H, Hei YJ, Lindsay MA, Rupin M, Cabaribere D, Lemmerick Y, Mackey JR.  Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomized, double-blind, placebo-controlled study. Lancet Oncol. 2011 Apr;12(4):369-76.
Craik AC, Veldhoen RA, Czernick M, Buckland TW, Kyselytzia K, Ghosh S, Lai R, Damaraju S, Underhill DA, Mackey JR, Goping IS. The BH-3 only Bad confers breast cancer taxane sensitivity through a nonapoptotic mechanism. Oncogene. 2010 Sep 30;29(30):5381-91.
Mackey JR, Galmarini CM, Graham K, Joy AA, Delmer, A, Dabbagh, L, Glubrecht D, Jewell LD, Lai R, Lang T, Young JD, Merle-Beral H, Binet PL, Cass CE, Dumontet C.  Quantitative RT-PCR analysis of nucleoside transporter and metabolism genes in Chronic Lymphocytic Leukemia: identification of fludarabine sensitive and –insensitive populations.  Blood, 105(2):767-74, 2005.
Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young JD, Dumontet C, Cass C, Lai R, Mackey JR. The absence of human Equilibrative Nucleoside Transporter 1 (hENT1) is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clinical Cancer Research, Oct 15;10(20):6956-61, 2004.